🎙️ AI is leaving the screen and entering the physical world. Our CEO John Fowler joins Progress, Potential, And Possibilities (@ProgressPotent1) to discuss the rise of embodied AI and how MBody AI is building the intelligence layer for autonomous workforces. From the Orchestrator platform to real-world deployments across hospitality environments, @john_fowler_jd shares how MBody AI is bringing AI and robotics together to coordinate work in the physical world. ▶️ Watch the full conversation: piped.video/watch?v=J8-jVVZL… $MBAI #MBodyAI #EmbodiedAI #Robotics #ArtificialIntelligence #Automation #FutureOfWork

For decades, biometric technology has been trying to answer a deceptively simple question: WHO ARE YOU? A face. A fingerprint. An iris. Today, AI can turn these biological characteristics into highly sophisticated mathematical representations and compare them against enormous identity databases. But something much bigger is happening. The technology is evolving from biometric recognition toward Vision AI - systems that can potentially recognize not just who is in an image, but what is happening around them. People. Vehicles. Objects. Weapons. Behavior. Events. And that raises some fascinating questions: How accurate is facial recognition in the messy real world? What happens when you search for one person among millions? Can AI actually understand human behavior - or is it still primarily recognizing patterns? How do we protect biometric information? And as generative AI becomes capable of creating increasingly convincing synthetic faces, voices and videos, are we entering an arms race between biometric authentication and AI-powered deception? On this episode of @ProgressPotent1 I'm joined by B. Scott Swann, CEO of @ROC_VisionaryAI and a longtime leader in biometrics, computer vision and identity technology. Scott spent nearly two decades at the @FBI before moving into senior leadership at MorphoTrak and IDEMIA National Security Solutions, and now leads ROC as it develops technologies spanning facial, fingerprint and iris recognition, liveness detection, video analytics and Vision AI. We've gone from asking AI: "Who is this?" Now we're asking: "What does AI actually see?" #AI #Biometrics #FacialRecognition #VisionAI #ComputerVision #ArtificialIntelligence #IdentityTechnology #FutureOfAI @CoreIR_

A robot can recognize a person. But can it understand one? As AI moves from our screens into the physical world, robots increasingly have to operate in environments that are messy, unpredictable and fundamentally human. They need to navigate around us. Understand our instructions. Predict our movements. Interpret context. Recognize when we're uncertain or confused. And sometimes, perhaps most importantly, know when they don't understand what we're trying to do. That's where the emerging concept of social intelligence comes in. On this episode of @ProgressPotent1 I spoke with Brian Hartzband, President of U.S. Operations at @GMEXRobotics, about the company's "Terminal + Brain" approach to physical AI and its planned strategic investment in MediaMeta.AI, which focuses on human behavioral modeling and social intelligence. We explored a bigger question: Can robots learn to understand human behavior - not just recognize it? And what would it take to prove that they actually can? From embodied AI and robot perception to human intent, social context, behavioral prediction and the challenges of putting autonomous machines into hospitals, restaurants, hotels and homes, this is where AI gets very interesting. Can robots understand us? #PhysicalAI #EmbodiedAI #Robotics #ArtificialIntelligence #SocialIntelligence #HumanoidRobots #Robots #AI #RoboticsTechnology #FutureOfRobotics #HumanRobotInteraction #MachineLearning #AutonomousRobots #FutureOfAI @CoreIR_

A robot can recognize a person. But can it understand one? As AI moves from our screens into the physical world, robots increasingly have to operate in environments that are messy, unpredictable and fundamentally human. They need to navigate around us. Understand our instructions. Predict our movements. Interpret context. Recognize when we're uncertain or confused. And sometimes, perhaps most importantly, know when they don't understand what we're trying to do. That's where the emerging concept of social intelligence comes in. On this episode of @ProgressPotent1 I spoke with Brian Hartzband, President of U.S. Operations at @GMEXRobotics, about the company's "Terminal + Brain" approach to physical AI and its planned strategic investment in MediaMeta.AI, which focuses on human behavioral modeling and social intelligence. We explored a bigger question: Can robots learn to understand human behavior - not just recognize it? And what would it take to prove that they actually can? From embodied AI and robot perception to human intent, social context, behavioral prediction and the challenges of putting autonomous machines into hospitals, restaurants, hotels and homes, this is where AI gets very interesting. Can robots understand us? Watch now - piped.video/watch?v=9yxb10xX… #PhysicalAI #EmbodiedAI #Robotics #ArtificialIntelligence #SocialIntelligence #HumanoidRobots #Robots #AI #RoboticsTechnology #FutureOfRobotics #HumanRobotInteraction #MachineLearning #AutonomousRobots #FutureOfAI @CoreIR_

For decades, biometric technology has been trying to answer a deceptively simple question: WHO ARE YOU? A face. A fingerprint. An iris. Today, AI can turn these biological characteristics into highly sophisticated mathematical representations and compare them against enormous identity databases. But something much bigger is happening. The technology is evolving from biometric recognition toward Vision AI - systems that can potentially recognize not just who is in an image, but what is happening around them. People. Vehicles. Objects. Weapons. Behavior. Events. And that raises some fascinating questions: How accurate is facial recognition in the messy real world? What happens when you search for one person among millions? Can AI actually understand human behavior - or is it still primarily recognizing patterns? How do we protect biometric information? And as generative AI becomes capable of creating increasingly convincing synthetic faces, voices and videos, are we entering an arms race between biometric authentication and AI-powered deception? On this episode of @ProgressPotent1 I'm joined by B. Scott Swann, CEO of @ROC_VisionaryAI and a longtime leader in biometrics, computer vision and identity technology. Scott spent nearly two decades at the @FBI before moving into senior leadership at MorphoTrak and IDEMIA National Security Solutions, and now leads ROC as it develops technologies spanning facial, fingerprint and iris recognition, liveness detection, video analytics and Vision AI. We've gone from asking AI: "Who is this?" Now we're asking: "What does AI actually see?" Watch now - piped.video/watch?v=Xnx9nJZ5… #AI #Biometrics #FacialRecognition #VisionAI #ComputerVision #ArtificialIntelligence #IdentityTechnology #FutureOfAI @CoreIR_

Embodied AI moving from screens to the physical world, coordinating autonomous workforces across hospitality, is a glimpse into the future of enterprise automation. The questions raised about human-machine collaboration and the need for humanoid robots are exactly what automotive is wrestling with on the factory floor. This is where AI moves from theory to tangible operations.

Embodied AI moving from screens to the physical world, coordinating autonomous workforces across hospitality, is a glimpse into the future of enterprise automation. The questions raised about human-machine collaboration and the need for humanoid robots are exactly what automotive is wrestling with on the factory floor. This is where AI moves from theory to tangible operations.

What if we could teach the immune system to stop attacking the liver? That's one of the biggest questions emerging from the science of Primary Biliary Cholangitis (PBC) - a rare autoimmune disease that disproportionately affects women and can cause progressive liver damage. But PBC isn't simply a story about liver enzymes and disease progression. For many patients, the most difficult parts of the disease can be invisible: debilitating fatigue, relentless itching, brain fog, anxiety about the future and the social stigma of an illness that other people simply can't see. A new national Voice of PBC survey from The @PBCers Organization, capturing the experiences of 210 people living with PBC, brings that hidden burden into sharp focus. On this episode of @ProgressPotent1, I spoke with Carol Roberts - @pbcercarol - President of @PBCers Organization, about what it's actually like to live with PBC - and where the science is headed. We explore: • Why PBC is so often discovered through routine bloodwork; • Why fatigue and pruritus can be so debilitating; • Why patients are still told, "You don't look sick"; • The evolution from ursodeoxycholic acid to newer therapies including elafibranor and seladelpar; • What the Ocaliva experience taught us about drug development; • Why improving a biomarker isn't necessarily the same as improving a patient's life; • And perhaps most intriguingly - whether the next generation of PBC therapies could move beyond treating the consequences of autoimmunity and toward immune tolerance and reprogramming. Could we eventually teach the immune system to leave the bile ducts alone? That's where the future of PBC research gets particularly fascinating. #PBC #PrimaryBiliaryCholangitis #AutoimmuneDisease #RareDisease #LiverDisease #Immunology #DrugDevelopment #WomensHealth #MedicalResearch #FutureOfMedicine @FINNPartners

What if we could teach the immune system to stop attacking the liver? That's one of the biggest questions emerging from the science of Primary Biliary Cholangitis (PBC) - a rare autoimmune disease that disproportionately affects women and can cause progressive liver damage. But PBC isn't simply a story about liver enzymes and disease progression. For many patients, the most difficult parts of the disease can be invisible: debilitating fatigue, relentless itching, brain fog, anxiety about the future and the social stigma of an illness that other people simply can't see. A new national Voice of PBC survey from The @PBCers Organization, capturing the experiences of 210 people living with PBC, brings that hidden burden into sharp focus. On this episode of @ProgressPotent1, I spoke with Carol Roberts - @pbcercarol - President of @PBCers Organization, about what it's actually like to live with PBC - and where the science is headed. We explore: • Why PBC is so often discovered through routine bloodwork; • Why fatigue and pruritus can be so debilitating; • Why patients are still told, "You don't look sick"; • The evolution from ursodeoxycholic acid to newer therapies including elafibranor and seladelpar; • What the Ocaliva experience taught us about drug development; • Why improving a biomarker isn't necessarily the same as improving a patient's life; • And perhaps most intriguingly - whether the next generation of PBC therapies could move beyond treating the consequences of autoimmunity and toward immune tolerance and reprogramming. Could we eventually teach the immune system to leave the bile ducts alone? That's where the future of PBC research gets particularly fascinating. Watch now - piped.video/watch?v=TcVl8QbC… #PBC #PrimaryBiliaryCholangitis #AutoimmuneDisease #RareDisease #LiverDisease #Immunology #DrugDevelopment #WomensHealth #MedicalResearch #FutureOfMedicine @FINNPartners

AI has spent the last few years transforming what happens on our screens. The next frontier may be what happens in the physical world. I recently spoke on @ProgressPotent1 with @john_fowler_jd, CEO of @MbodyAi, about a field increasingly known as embodied AI - artificial intelligence that can perceive its physical surroundings, make decisions and direct machines to perform real-world tasks. MBody AI is already deploying autonomous robots in large hospitality environments, where machines are performing tasks such as floor cleaning and generating operational data about how that work gets done. But the bigger idea is what happens beyond a single robot. MBody's Orchestrator platform is designed to provide an intelligence and coordination layer across robotic operations - potentially allowing different machines to work as a coordinated autonomous workforce. That raises some fascinating questions: 🧠 Can AI learn from thousands of hours of machines operating in the real world?; 🏢 Could an entire building eventually be managed by a combination of humans and autonomous machines?; 🤖 Do we need humanoid robots to automate physical work?; 👷 And what happens to the human workforce when AI moves from generating information to performing physical work? MBody AI recently became a Nasdaq-listed company under the ticker MBAI, making this an especially interesting moment to examine both the technology and the business behind it. The transition from AI that thinks to AI that acts may be one of the most consequential developments in robotics. My conversation with John Fowler explores where that future is already happening - and where it could go next. #ArtificialIntelligence #AI #Robotics #EmbodiedAI #AutonomousRobots #RoboticsAI #FutureOfWork #Automation #PhysicalAI #MachineLearning #RoboticsTechnology #MBodyAI #HospitalityTechnology #FutureOfWork #Innovation @CoreIR_ @MGMResortsIntl @MoheganSun @CaesarsPalace

AI has spent the last few years transforming what happens on our screens. The next frontier may be what happens in the physical world. I recently spoke on @ProgressPotent1 with @john_fowler_jd, CEO of @MbodyAi, about a field increasingly known as embodied AI - artificial intelligence that can perceive its physical surroundings, make decisions and direct machines to perform real-world tasks. MBody AI is already deploying autonomous robots in large hospitality environments, where machines are performing tasks such as floor cleaning and generating operational data about how that work gets done. But the bigger idea is what happens beyond a single robot. MBody's Orchestrator platform is designed to provide an intelligence and coordination layer across robotic operations - potentially allowing different machines to work as a coordinated autonomous workforce. That raises some fascinating questions: 🧠 Can AI learn from thousands of hours of machines operating in the real world?; 🏢 Could an entire building eventually be managed by a combination of humans and autonomous machines?; 🤖 Do we need humanoid robots to automate physical work?; 👷 And what happens to the human workforce when AI moves from generating information to performing physical work? MBody AI recently became a Nasdaq-listed company under the ticker MBAI, making this an especially interesting moment to examine both the technology and the business behind it. The transition from AI that thinks to AI that acts may be one of the most consequential developments in robotics. My conversation with John Fowler explores where that future is already happening - and where it could go next. Watch now - piped.video/watch?v=J8-jVVZL… #ArtificialIntelligence #AI #Robotics #EmbodiedAI #AutonomousRobots #RoboticsAI #FutureOfWork #Automation #PhysicalAI #MachineLearning #RoboticsTechnology #MBodyAI #HospitalityTechnology #FutureOfWork #Innovation @CoreIR_ @MGMResortsIntl @MoheganSun @CaesarsPalace

Thank you @irat1onal for hosting @CEO_VIDA! "Imaging is closer to the fundamental biology or mechanism of action of that drug...you can understand how it's functioning at a much finer level." #clinicaltrials #AI #imaging

Breast cancer isn't one disease. And that may be one of the most important things we need to understand when asking why some women experience more aggressive disease - and worse outcomes - than others. In my recent @ProgressPotent1 conversation with Dr. Joanne Mortimer, MD and Dr. Veronica Jones, MD of @cityofhope, we're going deep into one of the most complicated questions in modern oncology: Why does breast cancer behave differently across different populations? Is the answer in tumor biology? Genetic ancestry? Social vulnerability? Environmental exposures? Access to screening and treatment? Differences in the care patients receive? Or is it the interaction of all of these factors? Dr. Mortimer has spent decades helping translate advances in systemic breast cancer treatment into clinical care, from endocrine and HER2-targeted therapies to metastatic disease, molecular imaging, treatment resistance and survivorship. Dr. Jones brings another fascinating perspective - spanning breast surgical oncology, technology-enabled diagnostics, tumor biology, triple-negative breast cancer, endocrine therapy and some of the critical questions surrounding racial and ethnic disparities in breast cancer outcomes. Their work raises a profound possibility: What if studying why some populations experience worse outcomes could teach us something about the biology of breast cancer that ultimately benefits everyone? We're also talking about where breast cancer research goes next - precision oncology, gene expression, treatment resistance, early detection, AI, and the continuing challenge of turning discoveries in the laboratory into better outcomes in the real world. #BreastCancer #CancerResearch #Oncology #PrecisionMedicine #CancerDisparities #BreastCancerResearch #CancerBiology #WomenHealth #MedicalResearch #HealthcareInnovation #CityOfHope #CancerTreatment @RealChemistry_ @COHMedOnc @COH_SurgOnc

Breast cancer isn't one disease. And that may be one of the most important things we need to understand when asking why some women experience more aggressive disease - and worse outcomes - than others. In my recent @ProgressPotent1 conversation with Dr. Joanne Mortimer, MD and Dr. Veronica Jones, MD of @cityofhope, we're going deep into one of the most complicated questions in modern oncology: Why does breast cancer behave differently across different populations? Is the answer in tumor biology? Genetic ancestry? Social vulnerability? Environmental exposures? Access to screening and treatment? Differences in the care patients receive? Or is it the interaction of all of these factors? Dr. Mortimer has spent decades helping translate advances in systemic breast cancer treatment into clinical care, from endocrine and HER2-targeted therapies to metastatic disease, molecular imaging, treatment resistance and survivorship. Dr. Jones brings another fascinating perspective - spanning breast surgical oncology, technology-enabled diagnostics, tumor biology, triple-negative breast cancer, endocrine therapy and some of the critical questions surrounding racial and ethnic disparities in breast cancer outcomes. Their work raises a profound possibility: What if studying why some populations experience worse outcomes could teach us something about the biology of breast cancer that ultimately benefits everyone? We're also talking about where breast cancer research goes next - precision oncology, gene expression, treatment resistance, early detection, AI, and the continuing challenge of turning discoveries in the laboratory into better outcomes in the real world. Watch now - piped.video/watch?v=xS-P3mr3… #BreastCancer #CancerResearch #Oncology #PrecisionMedicine #CancerDisparities #BreastCancerResearch #CancerBiology #WomenHealth #MedicalResearch #HealthcareInnovation #CityOfHope #CancerTreatment @RealChemistry_ @COHMedOnc @COH_SurgOnc

What if one way to fight cancer isn't simply to kill cancer cells - but to reprogram the immune environment surrounding them? In this episode of @ProgressPotent1 I sit down with Dr. Joab Williamson, Ph.D. - VP Operations at @FaronPharm to explore the science and clinical development behind bexmarilimab, Faron's anti-Clever-1 antibody. Clever-1 is found on macrophages and is associated with an immunosuppressive immune environment. Faron's approach is designed to reprogram those macrophages rather than simply eliminate them, potentially improving antigen presentation and helping activate an anti-tumor T-cell response. We dig into: • How Clever-1 influences the tumor immune microenvironment; • What actually happens inside a macrophage when bexmarilimab binds Clever-1; • What Faron has learned from the BEXMAB study in MDS and AML; • The new randomized, placebo-controlled BEXERA trial; • BEAM-X and the potential use of bexmarilimab against MRD-positive AML after stem-cell transplant; • The @cityofhope investigator-initiated MDS study; • BLAZE and the attempt to overcome acquired resistance to PD-1 immunotherapy; • What the clinical data can - and cannot - tell us at this stage; • And perhaps the biggest question: Is macrophage reprogramming actually a fundamental way to change the course of cancer? A fascinating look at an emerging strategy at the intersection of immunology, macrophage biology, cancer, and drug development. #FaronPharmaceuticals #Bexmarilimab #CancerImmunotherapy #MDS #AML #Clever1 #Macrophages #CancerResearch #Biotechnology #Immunotherapy #ProgressPotentialAndPossibilities @FINNPartners @JuhoJalkanen

WHAT IF WE'VE BEEN PURIFYING MEDICINE TOO MUCH? 🌿💊 For decades, modern drug development has largely followed a powerful formula: Find the molecule. Isolate it. Purify it. Manufacture it. But what if, for some medicines derived from nature, the complexity itself is part of the therapeutic effect? That's the fascinating question I explored with @JoelStanley1 - CEO of @AJNABiosciences on @ProgressPotent1 Joel is one of @thestanleybros behind @charlottesweb, whose story became intertwined with the remarkable case of Charlotte Figi and helped propel CBD into the mainstream. Now he's taking that experience in a very different direction: developing pharmaceutical-grade botanical medicines under the FDA's relatively uncommon botanical-drug pathway. AJNA's approach is particularly intriguing because it doesn't necessarily attempt to reduce a plant or fungus to a single purified molecule. Instead, the company is asking whether we can: 🌱 Preserve nature's complex chemical compositions; 🔬 Characterize that complexity scientifically; 🏭 Manufacture it consistently from batch to batch; 💊 Develop it as a pharmaceutical; 📋 And ultimately prove its safety and efficacy through FDA-regulated clinical trials; AJNA's AJA001 is a full-spectrum cannabinoid program targeting irritability associated with autism spectrum disorder and has completed Phase 1, with Phase 2 development ahead. And AJA002 takes the concept into psychedelics - a full-spectrum tryptamine formulation being developed as a potential daily micro-dose for generalized anxiety disorder. That raises some fascinating questions: What if the active ingredient isn't always a single molecule? Can a mushroom become a prescription drug? Does a psychedelic medicine have to make you psychedelic? Can we preserve the complexity of nature while achieving the consistency demanded by modern pharmaceuticals? And perhaps the biggest question: Are we entering a post–single-molecule era of drug discovery? #BotanicalMedicine #Psychedelics #Psilocybin #CBD #Cannabis #DrugDevelopment #Biotech #FutureOfMedicine #AJNABioSciences #JoelStanley @ampragency

What if a CT scan isn't just a picture - but a quantitative map of human biology? For decades, medical imaging has largely been interpreted by human eyes. But advances in AI and quantitative imaging are changing that paradigm, allowing researchers to extract increasingly detailed measurements of anatomy, disease burden and treatment response from medical images. On this episode of @ProgressPotent1, I'm joined by Dr. Susan Wood, Ph.D. President & CEO of VIDA Intelligence - @vidalung - who has spent more than 25 years at the intersection of medical imaging, AI and clinical technology. Dr. Wood's own scientific journey began with her Ph.D. research at @JohnsHopkins where she used high-resolution CT imaging to quantify three-dimensional lung structure and relate those measurements to lung function. Today, VIDA is applying quantitative imaging and AI to pulmonary disease and clinical trials - including work supporting @AstraZeneca and their COPD development program. We talk about: 🔹 Why COPD is much more heterogeneous than conventional lung-function tests can reveal; 🔹 How AI can quantify emphysema, airways, lung structure and other features of disease; 🔹 The enormous challenge of standardizing CT imaging across hundreds of clinical-trial sites; 🔹 Why differences in scanners, protocols and patient breathing can create misleading measurements; 🔹 How imaging can become a source of digital biomarkers rather than simply diagnostic pictures; 🔹 What quantitative imaging can reveal about COPD that traditional clinical endpoints may not; 🔹 The role of imaging in AstraZeneca's OBERON and TITANIA COPD trials; 🔹 The emerging science of measuring mucus plugging and other structural features of COPD; 🔹 How researchers determine whether an AI-derived measurement is actually biologically meaningful; 🔹 And whether imaging biomarkers could eventually change how we design, conduct and evaluate clinical trials; The bigger question may be even more profound: What becomes possible when we stop thinking of medical images as pictures - and start thinking of them as data about human biology? #AI #MedicalImaging #COPD #DigitalBiomarkers #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #VIDAIntelligence @julesany

What if one way to fight cancer isn't simply to kill cancer cells - but to reprogram the immune environment surrounding them? In this episode of @ProgressPotent1 I sit down with Dr. Joab Williamson, Ph.D. - VP Operations at @FaronPharm to explore the science and clinical development behind bexmarilimab, Faron's anti-Clever-1 antibody. Clever-1 is found on macrophages and is associated with an immunosuppressive immune environment. Faron's approach is designed to reprogram those macrophages rather than simply eliminate them, potentially improving antigen presentation and helping activate an anti-tumor T-cell response. We dig into: • How Clever-1 influences the tumor immune microenvironment; • What actually happens inside a macrophage when bexmarilimab binds Clever-1; • What Faron has learned from the BEXMAB study in MDS and AML; • The new randomized, placebo-controlled BEXERA trial; • BEAM-X and the potential use of bexmarilimab against MRD-positive AML after stem-cell transplant; • The @cityofhope investigator-initiated MDS study; • BLAZE and the attempt to overcome acquired resistance to PD-1 immunotherapy; • What the clinical data can - and cannot - tell us at this stage; • And perhaps the biggest question: Is macrophage reprogramming actually a fundamental way to change the course of cancer? A fascinating look at an emerging strategy at the intersection of immunology, macrophage biology, cancer, and drug development. Watch now - piped.video/watch?v=pmCsk3jR… #FaronPharmaceuticals #Bexmarilimab #CancerImmunotherapy #MDS #AML #Clever1 #Macrophages #CancerResearch #Biotechnology #Immunotherapy #ProgressPotentialAndPossibilities @FINNPartners @JuhoJalkanen

WHAT IF WE'VE BEEN PURIFYING MEDICINE TOO MUCH? 🌿💊 For decades, modern drug development has largely followed a powerful formula: Find the molecule. Isolate it. Purify it. Manufacture it. But what if, for some medicines derived from nature, the complexity itself is part of the therapeutic effect? That's the fascinating question I explored with @JoelStanley1 - CEO of @AJNABiosciences on @ProgressPotent1 Joel is one of @thestanleybros behind @charlottesweb, whose story became intertwined with the remarkable case of Charlotte Figi and helped propel CBD into the mainstream. Now he's taking that experience in a very different direction: developing pharmaceutical-grade botanical medicines under the FDA's relatively uncommon botanical-drug pathway. AJNA's approach is particularly intriguing because it doesn't necessarily attempt to reduce a plant or fungus to a single purified molecule. Instead, the company is asking whether we can: 🌱 Preserve nature's complex chemical compositions; 🔬 Characterize that complexity scientifically; 🏭 Manufacture it consistently from batch to batch; 💊 Develop it as a pharmaceutical; 📋 And ultimately prove its safety and efficacy through FDA-regulated clinical trials; AJNA's AJA001 is a full-spectrum cannabinoid program targeting irritability associated with autism spectrum disorder and has completed Phase 1, with Phase 2 development ahead. And AJA002 takes the concept into psychedelics - a full-spectrum tryptamine formulation being developed as a potential daily micro-dose for generalized anxiety disorder. That raises some fascinating questions: What if the active ingredient isn't always a single molecule? Can a mushroom become a prescription drug? Does a psychedelic medicine have to make you psychedelic? Can we preserve the complexity of nature while achieving the consistency demanded by modern pharmaceuticals? And perhaps the biggest question: Are we entering a post–single-molecule era of drug discovery? Watch now - piped.video/watch?v=W5K0Ad5c… #BotanicalMedicine #Psychedelics #Psilocybin #CBD #Cannabis #DrugDevelopment #Biotech #FutureOfMedicine #AJNABioSciences #JoelStanley @ampragency